Diurnal, the physiological hormone replacement company, today announced that it had completed enrolment of 30-healthy volunteers and begun its Phase 1 Chronocort® study at Simbec Research located in Merthyr Tydfil (Wales, UK).
Chronocort® is a modified release hydrocortisone formulation for the treatment of Congenital Adrenal Hyperplasia and Adrenal Insufficiency both chronic, life-long disease. Diurnal has already received two Orphan Drug designations for the above indications from the European Medicines Agency (EMA), which affords ten years of market exclusivity after the grant of marketing authorisation in Europe.
Prof Richard Ross, Chief Scientific Officer, said:
"We are delighted to have started our Chronocort® Phase 1 study on schedule and expect to have read-out of the results during H2, 2011".